 FORT COLLINS, Colo., Aug. 9, 2021 PRNewswire -- Cytocom Inc. NASDAQ: CBLI, a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today provided an update regarding its portfolio of clinical programs. 